Current
15.7×
5-Year Average
16.6×
All-Time High
35.8×
All-Time Low
5.2×
P/FCF Ratio daily chart for Pfizer (PFE)
Jun 8, 2021 – Jun 5, 2026 · 1,255 trading days
Historical P/FCF Ratio for Pfizer (PFE) from 2001 to 2025
| 2025 | $141.50B | $9.08B | 15.6× | +0.3× | |
| 2024 | $150.35B | $9.84B | 15.3× | -18.6× | |
| 2023 | $162.58B | $4.79B | 33.9× | +22.9× | |
| 2022 | $287.71B | $26.03B | 11.1× | -0.0× | |
| 2021 | $331.62B | $29.87B | 11.1× | -6.5× | |
| 2020 | $204.74B | $11.61B | 17.6× | -2.9× | |
| 2019 | $205.57B | $9.99B | 20.6× | +3.0× | |
| 2018 | $239.51B | $13.63B | 17.6× | +3.2× | |
| 2017 | $204.71B | $14.25B | 14.4× | +0.9× | |
| 2016 | $186.90B | $13.90B | 13.4× | -1.1× | |
| 2015 | $188.92B | $13.02B | 14.5× | +2.4× | |
| 2014 | $185.92B | $15.30B | 12.2× | +0.7× | |
| 2013 | $187.10B | $16.30B | 11.5× | +0.4× | |
| 2012 | $173.97B | $15.73B | 11.1× | +2.6× | |
| 2011 | $156.59B | $18.58B | 8.4× | -4.9× | |
| 2010 | $132.95B | $9.94B | 13.4× | +5.8× | |
| 2009 | $116.58B | $15.38B | 7.6× | +0.8× | |
| 2008 | $112.80B | $16.54B | 6.8× | -5.9× | |
| 2007 | $146.02B | $11.47B | 12.7× | +1.4× | |
| 2006 | $175.36B | $15.54B | 11.3× | -1.5× | |
| 2005 | $162.02B | $12.63B | 12.8× | -1.0× | |
| 2004 | $190.21B | $13.74B | 13.8× | -14.1× | |
| 2003 | $254.07B | $9.10B | 27.9× | +6.9× | |
| 2002 | $176.98B | $8.43B | 21.0× | -12.3× | |
| 2001 | $234.90B | $7.06B | 33.3× | — |
- 202515.6×
- 202415.3×
- 202333.9×
- 202211.1×
- 202111.1×
- 202017.6×
- 201920.6×
- 201817.6×
- 201714.4×
- 201613.4×
- 201514.5×
- 201412.2×
- 201311.5×
- 201211.1×
- 20118.4×
- 201013.4×
- 20097.6×
- 20086.8×
- 200712.7×
- 200611.3×
- 200512.8×
- 200413.8×
- 200327.9×
- 200221.0×
- 200133.3×
About P/FCF Ratio at Pfizer (PFE)
Pfizer (PFE) P/FCF ratio is 15.7× as of June 5, 2026. The 5-year average is 16.6×. The sector median currently stands at 19.8×. The current ratio is at the 61th percentile of its own 10-year history.
Pfizer (PFE) historical P/FCF ratio has ranged from a low of 5.2× (2009) to a high of 35.8× (2024) in the available daily series.
The price-to-free-cash-flow (P/FCF) ratio compares a company's market capitalisation to its trailing twelve-month (TTM) free cash flow. It is calculated as market cap ÷ TTM free cash flow, where free cash flow = operating cash flow − capital expenditures. Because FCF cannot be inflated by non-cash accounting items, P/FCF is often considered a cleaner measure of "earnings-power valuation" than P/E — especially for capital-intensive businesses where depreciation diverges from real cash outflows.
Pfizer P/FCF Ratio by Year
Pfizer P/FCF Ratio 2025: 15.6×
Pfizer (PFE) P/FCF ratio in 2025 was 15.6×, expanded from 15.3× the prior year.
Pfizer P/FCF Ratio 2024: 15.3×
Pfizer (PFE) P/FCF ratio in 2024 was 15.3×, contracted from 33.9× the prior year.
Pfizer P/FCF Ratio 2023: 33.9×
Pfizer (PFE) P/FCF ratio in 2023 was 33.9×, expanded from 11.1× the prior year.
Pfizer P/FCF Ratio 2022: 11.1×
Pfizer (PFE) P/FCF ratio in 2022 was 11.1×, contracted from 11.1× the prior year.
Pfizer P/FCF Ratio 2021: 11.1×
Pfizer (PFE) P/FCF ratio in 2021 was 11.1×.
Sector peers by P/FCF Ratio — chart
Current ratio vs. sector peers. Highlighted bar is this company.
Sector peers by P/FCF Ratio — table
Healthcare peers of Pfizer (PFE), ranked by P/FCF ratio.
| 18.5× | |
| 17.8× | |
| 17.8× | |
| 16.9× | |
| 16.9× | |
| 16.4× | |
| 16.3× | |
| 15.9× | |
| 14.0× | |
| 13.5× | |
| 12.9× | |
| 12.5× | |
| 12.4× | |
| 12.2× | |
| 12.1× | |
| 11.3× | |
| 10.7× | |
| 10.4× | |
| 10.3× | |
| 10.0× | |
| 9.6× | |
| 9.1× | |
| 9.1× | |
| 6.9× | |
| 2.5× |
- 18.5×
- 17.8×
- 16.9×
- 16.4×
- 13.5×
- 12.9×
- 12.4×
- 10.7×
- 10.3×
- 9.1×
- 9.1×
- 6.9×
- 2.5×
Frequently asked questions
Pfizer (PFE) Key Financials
Charts, filings, and peer comparison for every metric